Prognostic Score for DCIS Linked With Survival After RT, Surgery

Share this content:
Patient prognostic score for ductal carcinoma in situ may be linked with the magnitude of the improvement in survival.
Patient prognostic score for ductal carcinoma in situ may be linked with the magnitude of the improvement in survival.

Patient prognostic score for ductal carcinoma in situ (DCIS) may be linked with the magnitude of the improvement in survival in patients treated with radiotherapy (RT) after breast-conserving surgery.1

These findings, which were published in the Journal of Clinical Oncology, suggested that decisions for RT may be tailored on the basis of patient factors, tumor biology, and prognostic score.

Researchers led by Yasuaki Sagara, MD, of Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, MA, conducted a retrospective longitudinal cohort study of 32 144 patients with DCIS diagnosed between 1988 and 2007 and treated with breast-conserving surgery. Among them, 20 329 were treated with RT and 11 815 were not.

They evaluated for breast cancer mortality between the 2 groups using Cox proportional hazards model with propensity score weighting.

In total, they found 304 breast cancer-specific deaths over a median follow-up of 96 months, with a cumulative incidence of breast cancer mortality at 10 years in the weighted cohorts of 1.8% in the RT group, and 2.1% in the non-RT group.

RELATED: Patients Who Self-reported Symptoms Experienced Improved Health-Related Quality of Life

The researchers only found significant improvements in survival in the RT group compared with the non-RT group among patients with higher nuclear grade, younger age, and larger tumor size. Magnitude of survival difference with RT was significantly correlated with prognostic score.

Reference

  1. Sagara Y, Freedman RA, Vaz-Luis I, et al. Patient prognostic score and associations with survival improvement offered by Radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a population-based longitudinal cohort study [published online ahead of print February 1, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.65.1869.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters